Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer

CD8(+)CD103(+) tissue-resident memory T cells (TRMs) are involved in tumor immune response and linked to favorable clinical outcome in human cancer. However, the distribution, phenotype, functional properties and clinical relevance of these cells in gastric cancer (GC) remain elusive. Here, our data show that, in comparison to non-tumor tissues, the percentages of CD8(+)CD103(+) TRMs in tumors are significantly decreased. Most tumor-infiltrating CD8(+)CD103(+) TRMs are CD45RA(-)CCR7(-) effector-memory cells with higher PD-1 and 4-1BB expression than those from non-tumor tissues. Further, tumor-infiltrating CD8(+)CD103(+) TRMs show impaired cytolytic capacity due to decreased granzyme B and perforin expression. Moreover, ex vivo PD-1 blockade could restore the cytolytic capacity of tumor-infiltrating CD8(+)CD103(+) TRMs, and such anti-PD-1-mediated reinvigoration of CD8(+)CD103(+) TRMs could be further enhanced by 4-1BB co-stimulation. Finally, lower levels of Tumor-infiltrating CD8(+)CD103(+) TRMs are positively correlated with GC progression and poor patients' survival. Our data suggest that restoring CD8(+)CD103(+) TRM function by combining PD-1 blockade and 4-1BB co-stimulation may be a promising strategy for treating GC.

Automated summary

In gastric cancer, tumor-infiltrating CD8(+)CD103(+) tissue-resident memory T cells are decreased compared to non-tumor tissues and show impaired cytolytic function. Restoring the function of these cells through PD-1 blockade and 4-1BB co-stimulation may be a promising strategy for treating gastric cancer and improving patient survival.